RT Journal Article SR Electronic T1 Single-cell RNA Analysis on ACE2 Expression Provides Insight into SARS-CoV-2 Blood Entry and Heart Injury JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.03.31.20047621 DO 10.1101/2020.03.31.20047621 A1 Jieyu Guo A1 Xiangxiang Wei A1 Qinhan Li A1 Liliang Li A1 Zhaohua Yang A1 Yu Shi A1 Yue Qin A1 Xinyue Zhang A1 Xinhong Wang A1 Xiuling Zhi A1 Dan Meng YR 2020 UL http://medrxiv.org/content/early/2020/04/04/2020.03.31.20047621.abstract AB COVID-19 is a global pandemic with high infectivity and pathogenicity, accounting for tens of thousands of deaths worldwide. Recent studies have found that the pathogen of COVID-19, SARS-CoV-2, shares the same cell receptor Angiotensin converting enzyme II (ACE2) with SARS-CoV. The pathological investigation of COVID-19 death showed that the lung had the characteristics of pulmonary fibrosis. However, how SARS-CoV-2 spreads from the lungs to other organs has not yet been determined. Here, we performed an unbiased evaluation of cell-type specific expression of ACE2 in healthy and fibrotic lungs, as well as in normal and failed adult human hearts, using published single-cell RNA-seq data. We found that ACE2 expression in fibrotic lungs mainly locates in arterial vascular cells, which might provide the route for bloodstream spreading of SARS-CoV-2. The failed human hearts have a higher percentage of ACE2-expressing cardiomyocytes, and SARS-CoV-2 might attack cardiomyocytes through the bloodstream in patients with heart failure.Moreover, ACE2 was highly expressed in cells infected by RSV or MERS-CoV and in mice treated by LPS. Our findings indicate that patients with pulmonary fibrosis, heart failure, and virus infection have a higher risk and are more susceptible to SARS-CoV-2 infection. SARS-CoV-2 might attack other organs by getting into the bloodstream. This work provides new insights into SARS-CoV-2 blood entry and heart injury and might propose a therapeutic strategy to prevent patients from developing severe complications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Shanghai Science and Technology Commission of China (19JC1411300 to D. Meng), General Programs (81873469 to D. Meng, 81873536 to X. Wang, 81572713 to X. Zhi), and the Great Program (91639103 to D. Meng) of the National Natural Science Foundation of China, and China Postdoctoral Science Foundation (2019M651371 and 2019T120303 to X. Wei). Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublic data for normal and fibrotic lungs scRNA-seq is available in GSE132771. Public data for healthy hearts scRNA-seq was available in GSE109816, failed hearts scRNA-seq in GSE121893. Public data for respiratory syncytial virus infection RNA-seq is available in GSE140226, MERS-CoV in GSE139516, and LPS injection in GSE136848.